0000887247
false
--12-31
0000887247
2023-09-06
2023-09-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): September
6, 2023
DMK PHARMACEUTICALS CORPORATION
(Exact Name of Registrant as Specified in Charter)
Delaware |
|
0-26372 |
|
82-0429727 |
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
11682 El Camino Real, Suite 300
San Diego, CA |
|
92130 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including area
code: (858) 997-2400
Adamis Pharmaceuticals Corporation
(Former name or Former Address, if Changed Since Last
Report)
___________________________________________
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Exchange Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on
which registered |
Common Stock |
|
DMK |
|
NASDAQ Capital Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
Emerging growth company ☐ |
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.03 | Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year |
Effective
September 6, 2023, Adamis Pharmaceuticals Corporation (the “Company”) changed its corporate name to DMK Pharmaceuticals Corporation
(the “Name Change”) pursuant to a certificate of amendment to the Company’s restated certificate of incorporation (the
“Charter Amendment”) filed with the Secretary of State of Delaware. On the effective date of the Name Change the Company
also amended and restated its Amended and Restated Bylaws (the “Amended and Restated Bylaws”), to reflect the Name Change.
Pursuant to Delaware law, a stockholder vote was not necessary to effectuate the Name Change, and the Name Change does not affect the
rights of the Company’s stockholders. Other than the Name Change, the Company did not make any changes to its certificate
of incorporation or Amended and Restated Bylaws.
The
Company’s common stock will begin trading under the new ticker symbol “DMK” on The Nasdaq Capital Market on or about
September 8, 2023. Except as described in the preceding sentence, the Name Change does not affect the Company’s trading symbol,
its CUSIP, nor the rights of its security holders, creditors, customers or suppliers.
Copies
of the Charter Amendment and the Amended and Restated Bylaws are filed as Exhibit 3.1 and Exhibit 3.2, respectively, with
this Current Report on Form 8-K and are incorporated herein by reference. On September 7, 2023, the Company issued a press release regarding
the Name Change. A copy of the press release is attached as Exhibit 99.1 and is incorporated by reference.
|
Item 9.01 |
Financial Statements and Exhibits |
(d) Exhibits
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ADAMIS PHARMACEUTICALS CORPORATION |
|
|
|
|
|
|
|
|
|
Dated: September 7, 2023 |
By: |
/s/ David J. Marguglio |
|
Name: |
David J. Marguglio |
|
Title: |
President |
DMK Pharmaceuticals Corporation 8-K
Exhibit 3.1
CERTIFICATE
OF AMENDMENT TO THE
RESTATED
CERTIFICATE OF INCORPORATION OF
ADAMIS
PHARMACEUTICALS CORPORATION
Adamis
Pharmaceuticals Corporation, a corporation organized under and existing under the laws of the State of Delaware (the “Company”),
certifies that:
FIRST:
The name of the Company is Adamis Pharmaceuticals Corporation.
SECOND:
The Board of Directors of the Company, acting in accordance with the provisions of Sections 141 and 242 of the Delaware General Corporation
Law (the “DGCL”), duly approved and adopted resolutions to amend Article I of the Restated Certificate of Incorporation of
the Company, which is hereby amended as follows:
“I.
The
name of this corporation is DMK Pharmaceuticals Corporation (the “Company”).”
THIRD:
That this Certificate of Amendment to the Restated Certificate of Incorporation of the Company has been duly adopted in accordance with
Section 242 of the DGCL.
IN
WITNESS WHEREOF, this Certificate of Amendment to the Restated Certificate of Incorporation has been duly executed by its authorized
officer on this 6th day of September, 2023.
|
ADAMIS PHARMACEUTICALS CORPORATION |
|
|
|
|
|
|
By: |
/s/ Ehrahim Versi |
|
|
|
Ebrahim Versi |
|
|
|
Chief Executive Officer |
|
DMK Pharmaceuticals Corporation 8-K
Exhibit 3.2
AMENDED
AND RESTATED
BYLAWS
OF
DMK PHARMACEUTICALS CORPORATION
ARTICLE I
OFFICES
Section 1. Registered
Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle.
Section 2. Other
Offices. The corporation shall also have and maintain an office or principal place of business at such place as may be fixed by the
Board of Directors, and may also have offices at such other places, both within and without the State of Delaware as the Board of Directors
may from time to time determine or the business of the corporation may require.
ARTICLE II
CORPORATE SEAL
Section 3. Corporate
Seal. The Board of Directors may adopt a corporate seal. The corporate seal shall consist of a die bearing the name of the corporation
and the inscription, “Corporate Seal-Delaware”. Said seal may be used by causing it or a facsimile thereof to be impressed
or affixed or reproduced or otherwise.
ARTICLE III
STOCKHOLDERS’ MEETINGS
Section 4. Place
of Meetings. Meetings of the stockholders of the corporation may be held at such place, either within or without the State of Delaware,
as may be determined from time to time by the Board of Directors. The Board of Directors may, in its sole discretion, determine that
the meeting shall not be held at any place, but may instead be held solely by means of remote communication as provided under the Delaware
General Corporation Law (the “DGCL”).
Section 5. Annual
Meetings.
(a) The annual meeting of the stockholders of the corporation, for the purpose of election of directors and for such other business as
may lawfully come before it, shall be held on such date and at such time as may be designated from time to time by the Board of Directors.
Nominations of persons for election to the Board of Directors of the corporation and the proposal of business to be considered by the
stockholders may be made at an annual meeting of stockholders: (i) pursuant to the corporation’s notice of meeting of stockholders;
(ii) by or at the direction of the Board of Directors; or (iii) by any stockholder of the corporation who was a stockholder
of record at the time of giving the stockholder’s notice provided for in the following paragraph, who is entitled to vote at the
meeting and who complied with the notice procedures set forth in this Section 5.
(b)
At an annual meeting
of the stockholders, only such business shall be conducted as shall have been properly brought before the meeting. For nominations or
other business to be properly brought before an annual meeting by a stockholder pursuant to clause (iii) of Section 5(a) of
these Amended and Restated Bylaws, (i) the stockholder must have given timely notice thereof in writing to the Secretary of the
corporation, (ii) such other business must be a proper matter for stockholder action under DGCL, (iii) if the stockholder,
or the beneficial owner on whose behalf any such proposal or nomination is made, has provided the corporation with a Solicitation Notice
(as defined in clause (iii) of the last sentence of this Section 5(b)), such stockholder or beneficial owner must, in the case of
a proposal, have delivered a proxy statement and form of proxy to holders of at least the percentage of the corporation’s voting
shares required under applicable law to carry any such proposal, or, in the case of a nomination or nominations, have delivered a proxy
statement and form of proxy to holders of a percentage of the corporation’s voting shares reasonably believed by such stockholder
or beneficial owner to be sufficient to elect the nominee or nominees proposed to be nominated by such stockholder, and must, in either
case, have included in such materials the Solicitation Notice, and (iv) if no Solicitation Notice relating thereto has been timely
provided pursuant to this section, the stockholder or beneficial owner proposing such business or nomination must not have solicited
a number of proxies sufficient to have required the delivery of such a Solicitation Notice under this Section 5. To be timely, a
stockholder’s notice must be received by the Secretary at the principal executive offices of the corporation not later than the
close of business on the 90th day nor earlier than the close of business on the 120th day prior to the
first anniversary of the date of the preceding year’s annual meeting; provided, however, that subject to the next sentence of this
Section 5(b), in the event that the date of the annual meeting is changed by more than 30 days before or after such anniversary
date (or if no annual meeting was held in the preceding year), notice by the stockholder to be timely must be so received not earlier
than the close of business on the 120th day prior to the date of such annual meeting and not later than the later of
the close of business on the later of the 90th day prior to the date of such annual meeting or the 10th day
following the day on which public announcement of the date of such meeting is first made. In no event shall an adjournment, or postponement,
of an annual or special meeting for which notice has been given (or any announcement of any such adjournment or postponement), commence
a new time period (or extend any time period) for the giving of a stockholder’s notice as described above. Such stockholder’s
notice shall set forth: (A) as to each person whom the stockholder proposes to nominate for election or reelection as a director
all information relating to such person that is required to be disclosed in solicitations of proxies for election of directors in an
election contest, or is otherwise required, in each case pursuant to Regulation 14A under the Securities Exchange Act of 1934, as
amended (the “1934 Act”) and Rule 14a-4(d) thereunder (including such person’s written consent to being
named in the proxy statement as a nominee and to serving as a director if elected); (B) as to any other business that the stockholder
proposes to bring before the meeting, a brief description of the business desired to be brought before the meeting, the reasons for conducting
such business at the meeting and any material interest in such business of such stockholder and the beneficial owner, if any, on whose
behalf the proposal is made; and (C) as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the
nomination or proposal is made (X) the name and address of such stockholder, as they appear on the corporation’s books, and
of such beneficial owner, (Y) the class and number of shares of the corporation which are owned beneficially and of record by such
stockholder and such beneficial owner, and (Z) whether either such
stockholder or beneficial
owner intends to deliver a proxy statement and form of proxy to holders of, in the case of the proposal, at least the percentage of the
corporation’s voting shares required under applicable law to carry the proposal or, in the case of a nomination or nominations,
a sufficient number of holders of the corporation’s voting shares to elect such nominee or nominees (an affirmative statement of
such intent, a “Solicitation Notice”).
(c)
Notwithstanding anything in the third sentence of Section 5(b) of these Amended and Restated
Bylaws to the contrary, in the event that the number of directors to be elected to the Board of Directors of the corporation is increased
and there is no public announcement by the corporation of the appointment of a director, or, if no appointment was made, of the vacancy,
made by the corporation at least ten (10) days before the last day a stockholder may deliver a notice of nomination in accordance
with the third sentence of Section 5(b), a stockholder’s notice required by this Section 5 and which complies with the
requirements in Section 5(b), other than the timing requirements in the third sentence of Section 5(b), shall also be considered
timely, but only with respect to nominees for any new positions created by such increase, if it shall be delivered to the Secretary at
the principal executive offices of the corporation not later than the close of business on the 10th day following the day on which
such public announcement is first made by the corporation.
(d)
Only such persons who are nominated in accordance with the procedures set forth in this Section 5
shall be eligible to serve as directors and only such business shall be conducted at a meeting of stockholders as shall have been brought
before the meeting in accordance with the procedures set forth in this Section 5. Except as otherwise provided by law, the Chairman
of the meeting shall have the power and duty to determine whether a nomination or any business proposed to be brought before the meeting
was made, or proposed, as the case may be, in accordance with the procedures set forth in these Amended and Restated Bylaws and, if any
proposed nomination or business is not in compliance with these Amended and Restated Bylaws, to declare that such defective proposal or
nomination shall not be presented for stockholder action at the meeting and shall be disregarded.
(e)
Notwithstanding the foregoing provisions of this Section 5, in order to include information
with respect to a stockholder proposal in the proxy statement and form of proxy for a stockholders’ meeting, a stockholder must
also comply with all applicable requirements of the 1934 Act and the rules and regulations thereunder with respect to matters set forth
in this Section 5. Nothing in these Amended and Restated Bylaws shall be deemed to affect any rights of stockholders to request inclusion
of proposals in the corporation’s proxy statement pursuant to Rule 14a-8 under the 1934 Act.
(f)
For purposes of this Section 5, “public announcement” shall mean disclosure
in a press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly
filed by the corporation with the Securities and Exchange Commission pursuant to Section 13, 14 or 15(d) of the 1934 Act.
Section 6. Special
Meetings.
(a)
Special meetings of the stockholders of the corporation may be called, for any purpose or purposes,
by (i) the Chairman of the Board of Directors, (ii) the
President or Chief
Executive Officer, (iii) the Board of Directors, or (iv) the holders of shares representing at least 25% of all votes entitled to
be cast of any issue proposed to be considered at the meeting, and shall be held at such place, on such date, and such time as the Board
of Directors shall fix. At any time or times that the corporation is subject to Section 2115(b) of the California General Corporation
Law (“CGCL”), stockholders holding five percent (5%) or more of the outstanding shares shall have the right
to call a special meeting of stockholders as set forth in Section 18(b) herein.
(b)
If a special meeting is properly called by any person or persons other than the Board of Directors,
the request shall be in writing, specifying the general nature of the business proposed to be transacted, and shall be delivered personally
or sent by certified or registered mail, return receipt requested, to the Chairman of the Board of Directors, the Chief Executive Officer,
or the Secretary of the corporation. No business may be transacted at such special meeting otherwise than specified in such notice. The
Board of Directors shall determine the time and place of such special meeting, which shall be held not less than 35 nor more than 120 days
after the date of the receipt of the request. Upon determination of the time and place of the meeting, the officer receiving the request
shall cause notice to be given to the stockholders entitled to vote, in accordance with the provisions of Section 7 of these Amended
and Restated Bylaws. Nothing contained in this paragraph (b) shall be construed as limiting, fixing, or affecting the time when a
meeting of stockholders called by action of the Board of Directors may be held.
(c)
Nominations of persons for election to the Board of Directors may be made at a special meeting
of stockholders at which directors are to be elected pursuant to the corporation’s notice of meeting (i) by or at the direction
of the Board of Directors, or (ii) by any stockholder of the corporation who is a stockholder of record at the time of giving notice
provided for in these Amended and Restated Bylaws who shall be entitled to vote at the meeting and who complies with the notice procedures
set forth in this Section 6(c). In the event the corporation calls a special meeting of stockholders for the purpose of electing
one or more directors to the Board of Directors, any such stockholder may nominate a person or persons (as the case may be), for election
to such position(s) as specified in the corporation’s notice of meeting, if the stockholder’s notice required by Section 5(b)
(which shall also be required by this Section 6(c)) of these Amended and Restated Bylaws shall be received by to the Secretary at the
principal executive offices of the corporation not earlier than the close of business on the 120th day prior to the date
of such special meeting and not later than the close of business on the later of the 90th day prior to the date of such
meeting or the 10th day following the day on which public announcement is first made of the date of the special meeting
and of the nominees proposed by the Board of Directors to be elected at such meeting. In no event shall the public announcement of an
adjournment or postponement of a special meeting commence a new time period (or extend any time period) for the giving of a stockholder’s
notice as described above.
(d)
Notwithstanding the foregoing provisions of this Section 6, a stockholder must also comply
with all applicable requirements of the 1934 Act and the rules and regulations thereunder with respect to matters set forth in this Section 6.
Nothing in these Bylaws shall be deemed to affect any rights of stockholders to request inclusion of proposals in the corporation’s
proxy statement pursuant to Rule 14a-8 under the 1934 Act.
Section 7. Notice
of Meetings. Except as otherwise provided by law, notice, given in writing or by electronic transmission, of each meeting of stockholders
shall be given not less than 10 nor more than 60 days before the date of the meeting to each stockholder entitled to vote at such
meeting, such notice to specify the place, if any, date and hour, in the case of special meetings, the purpose or purposes of the meeting,
and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote
at any such meeting. If mailed, notice is deemed given when deposited in the United States mail, postage prepaid, directed to the stockholder
at such stockholder’s address as it appears on the records of the corporation. If sent via electronic transmission, notice is deemed
given as of the sending time recorded at the time of transmission. Notice of the time, place, if any, and purpose of any meeting of stockholders
may be waived in writing, signed by the person entitled to notice thereof, or by electronic transmission by such person, either before
or after such meeting, and will be waived by any stockholder by his attendance thereat in person, by remote communication, if applicable,
or by proxy, except when the stockholder attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the
transaction of any business because the meeting is not lawfully called or convened. Any stockholder so waiving notice of such meeting
shall be bound by the proceedings of any such meeting in all respects as if due notice thereof had been given.
Section 8. Quorum.
Except as otherwise provided by law or by the certificate of incorporation of the corporation, as amended and/or restated from time
to time (the “Restated Certificate of Incorporation”), at all meetings of stockholders, the presence, in person, by remote
communication, if applicable, or by proxy, of both (i) the holders of a majority in voting power of the capital stock issued and outstanding
and entitled to vote on one or more matters to be voted on at the meeting, and (ii) the holders of at least one-third of all issued and
outstanding shares of Common Stock entitled to vote, shall constitute a quorum at all meetings of the stockholders for the transaction
of business. In the absence of a quorum, any meeting of stockholders may be adjourned, from time to time, either by the chairman of the
meeting or by vote of the holders of a majority in voting power of the shares represented thereat, but no other business shall be transacted
at such meeting. The stockholders present at a duly called or convened meeting, at which a quorum is present, may continue to transact
business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum. Except as otherwise provided
by law or (if then-applicable to the corporation) by applicable stock exchange or Nasdaq Stock Market rules, or by the Restated Certificate
of Incorporation or these Amended and Restated Bylaws, in all matters other than the election of directors, the affirmative vote of a
majority of the votes properly cast on the matter affirmatively or negatively (excluding any abstentions or broker non-votes) shall be
the act of the stockholders. For purposes of these Amended and Restated Bylaws, a share present at a meeting, but for which there is an
abstention, shall be counted as present for the purpose of establishing a quorum but shall not be counted as a vote cast. Except as otherwise
provided by law, the Restated Certificate of Incorporation or these Amended and Restated Bylaws, directors shall be elected by a plurality
of all votes properly cast. Where a separate vote by a class or classes or series is required, except where otherwise provided by law
or by the Restated Certificate of Incorporation or these Amended and Restated Bylaws, a majority in voting power of the outstanding shares
of such class or classes or series, present in person, by remote communication, if applicable, or represented by proxy duly authorized,
shall constitute a quorum entitled to take action with respect to that vote on that matter. Except where otherwise provided
by law or by the
Restated Certificate of Incorporation or these Amended and Restated Bylaws, the affirmative vote of the majority (plurality, in the case
of the election of directors) of the votes properly cast on the matter affirmatively or negatively shall be the act of such class or classes
or series.
Section 9. Adjournment
and Notice of Adjourned Meetings. Any meeting of stockholders, whether annual or special, may be adjourned from time to time either
by the chairman of the meeting or by the vote of a majority in voting power of the shares present in person, by remote communication,
if applicable, or represented by proxy at the meeting. When a meeting is adjourned to another time or place, if any, notice need not be
given of the adjourned meeting if the time and place, if any, and the means of remote communications, if any, by which stockholders and
proxyholders may be deemed to be present in person and vote at such adjourned meeting, thereof are announced at the meeting at which the
adjournment is taken. At the adjourned meeting, the corporation may transact any business which might have been transacted at the original
meeting. If the adjournment is for more than 30 days or if after the adjournment a new record date is fixed for the adjourned meeting,
a notice of the adjourned meeting, and the means of remote communications, if any, by which stockholders and proxyholders may be deemed
to be present in person and vote at such adjourned meeting, shall be given to each stockholder of record entitled to vote at the meeting.
Section 10. Voting
Rights. For the purpose of determining those stockholders entitled to vote at any meeting of the stockholders, except as otherwise
provided by law, only persons in whose names shares stand on the stock records of the corporation on the record date, as provided in Section 12
of these Amended and Restated Bylaws, shall be entitled to vote at any meeting of stockholders. Every person entitled to vote shall have
the right to do so either in person, by remote communication, if applicable, or by an agent or agents authorized by a proxy granted in
accordance with Delaware law. An agent so appointed need not be a stockholder. No proxy shall be voted after three years from its date
of creation, unless the proxy provides for a longer period.
Section 11. Joint
Owners of Stock. If shares or other securities having voting power stand of record in the names of two or more persons, whether fiduciaries,
members of a partnership, joint tenants, tenants in common, tenants by the entirety, or otherwise, or if two or more persons have the
same fiduciary relationship respecting the same shares, unless the Secretary is given written notice to the contrary and is furnished
with a copy of the instrument or order appointing them or creating the relationship wherein it is so provided, their acts with respect
to voting shall have the following effect: (a) if only one votes, his act binds all; (b) if more than one votes, and the vote
is not evenly split on a particular matter, the act of the majority so voting binds all; (c) if more than one votes, but the vote
is evenly split on any particular matter, each faction may vote the securities in question proportionally, or may apply to the Delaware
Court of Chancery for relief as provided in the DGCL, Section 217(b). If the instrument filed with the Secretary shows that any such
tenancy is held in unequal interests, a majority or even-split for the purpose of subsection (c) shall be a majority or even-split
in interest.
Section 12. List
of Stockholders. The Secretary shall prepare and make, at least 10 days before every meeting of stockholders, a complete list
of the stockholders entitled to vote
at said meeting,
arranged in alphabetical order, showing the address of each stockholder and the number of shares registered in the name of each stockholder.
Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, (a) on a reasonably accessible
electronic network, provided that the information required to gain access to such list is provided with the notice of the meeting, or
(b) during ordinary business hours, at the principal place of business of the corporation. In the event that the corporation determines
to make the list available on an electronic network, the corporation may take reasonable steps to ensure that such information is available
only to stockholders of the corporation. The list shall be open to examination of any stockholder during the time of the meeting as provided
by law.
Section 13. Action
Without Meeting. No action shall be taken by the stockholders, except at an annual or special meeting of stockholders called in accordance
with these Amended and Restated Bylaws, and no action shall be taken by the stockholders by written consent or by electronic transmission.
Section 14. Organization.
(a)
At every meeting of stockholders, the Chairman of the Board of Directors, or, if a Chairman has
not been appointed or is absent, the President, or, if the President is absent, a chairman of the meeting chosen by a majority in interest
of the stockholders entitled to vote, present in person or by proxy duly authorized, shall act as chairman. The Secretary, or, in his
absence, an Assistant Secretary directed to do so by the President, shall act as secretary of the meeting.
(b)
The Board of Directors of the corporation shall be entitled to make such rules or regulations
for the conduct of meetings of stockholders as it shall deem necessary, appropriate or convenient. Subject to such rules and regulations
of the Board of Directors, if any, the chairman of the meeting shall have the right and authority to prescribe such rules, regulations
and procedures and to do all such acts as, in the judgment of such chairman, are necessary, appropriate or convenient for the proper conduct
of the meeting, including, without limitation, establishing an agenda or order of business for the meeting, rules and procedures for maintaining
order at the meeting and the safety of those present, limitations on participation in such meeting to stockholders of record of the corporation
and their duly authorized and constituted proxies and such other persons as the chairman shall permit, restrictions on entry to the meeting
after the time fixed for the commencement thereof, limitations on the time allotted to questions or comments by participants and regulation
of the opening and closing of the polls for balloting on matters which are to be voted on by ballot. The date and time of the opening
and closing of the polls for each matter upon which the stockholders will vote at the meeting shall be announced at the meeting. Unless
and to the extent determined by the Board of Directors or the chairman of the meeting, meetings of stockholders shall not be required
to be held in accordance with rules of parliamentary procedure.
ARTICLE IV
DIRECTORS
Section 15. Number
and Term of Office. The authorized number of directors of the corporation shall be fixed by the Board of Directors from time to time.
Directors need not be
stockholders, unless
so required by the Restated Certificate of Incorporation. If for any reason, the directors shall not have been elected at an annual meeting,
they may be elected as soon thereafter as convenient.
Section 16. Powers.
The powers of the corporation shall be exercised, its business conducted and its property controlled by the Board of Directors, except
as may be otherwise provided by statute or by the Restated Certificate of Incorporation.
Section 17. Term
of Directors.
(a)
Subject to the rights of the holders of any series of Preferred Stock to elect additional directors
under specified circumstances, the directors shall be elected at each annual meeting of stockholders for a term of one year. Notwithstanding
the foregoing provisions of this section, each director shall serve until his successor is duly elected and qualified or until his earlier
death, resignation or removal. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any
incumbent director.
(b)
No stockholder entitled to vote at an election for directors may cumulate votes to which such
stockholder is entitled, unless, at the time of such election, the corporation is subject to Section 2115(b) of the CGCL. During
such time or times that the corporation is subject to Section 2115(b) of the CGCL, every stockholder entitled to vote at an election
for directors may cumulate such stockholder’s votes and give one candidate a number of votes equal to the number of directors to
be elected multiplied by the number of votes to which such stockholder’s shares are otherwise entitled, or distribute the stockholder’s
votes on the same principle among as many candidates as such stockholder thinks fit. No stockholder, however, shall be entitled to so
cumulate such stockholder’s votes, unless (i) the names of such candidate or candidates have been placed in nomination prior to
the voting and (ii) the stockholder has given notice at the meeting, prior to the voting, of such stockholder’s intention to cumulate
such stockholder’s votes. If any stockholder has given proper notice to cumulate votes, all stockholders may cumulate their votes
for any candidates who have been properly placed in nomination. Under cumulative voting, the candidates receiving the highest number of
votes, up to the number of directors to be elected, are elected.
Section 18. Vacancies.
(a)
Unless otherwise provided in the Certificate of Incorporation, and subject to the rights of the
holders of any series of Preferred Stock, any vacancies on the Board of Directors resulting from death, resignation, disqualification,
removal or other causes and any newly created directorships resulting from any increase in the number of directors shall, unless the Board
of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by stockholders, be filled
only by the affirmative vote of a majority of the directors then in office, even though less than a quorum of the Board of Directors,
or by a sole remaining director, provided, however, that whenever the holders of any class or classes of stock or series thereof
are entitled to elect one or more directors by the provisions of the Certificate of Incorporation, vacancies and newly created directorships
of such class or classes or series shall, unless the Board of Directors determines by resolution that any such vacancies or newly created
directorships shall be filled by stockholders, be filled by a majority of the directors
elected by such class
or classes or series thereof then in office, or by a sole remaining director so elected. Any director elected in accordance with the preceding
sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until
such director’s successor shall have been elected and qualified. A vacancy in the Board of Directors shall be deemed to exist under
this Bylaw in the case of the death, removal or resignation of any director.
(b)
At any time or times that the corporation is subject to Section 2115(b) of the CGCL, if,
after the filling of any vacancy, the directors then in office who have been elected by stockholders shall constitute less than a majority
of the directors then in office, then
(1)
any holder or holders of an aggregate of five percent (5%) or more of the total number of shares
at the time outstanding having the right to vote for those directors may call a special meeting of stockholders; or
(2)
the Superior Court of the proper county shall, upon application of such stockholder or stockholders,
summarily order a special meeting of the stockholders, to be held to elect the entire board, all in accordance with Section 305(c)
of the CGCL, the term of office of any director shall terminate upon that election of a successor. (CGCL §305(c).
Section 19. Resignation.
Any director may resign at any time by delivering his or her notice in writing or by electronic transmission to the Secretary, such
resignation to specify whether it will be effective at a particular time, upon receipt by the Secretary or at the pleasure of the Board
of Directors. If no such specification is made, it shall be deemed effective at the pleasure of the Board of Directors. When one or more
directors shall resign from the Board of Directors, effective at a future date, a majority of the directors then in office, including
those who have so resigned, shall have power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation
or resignations shall become effective, and each director so chosen shall hold office for the unexpired portion of the term of the director
whose place shall be vacated and until his successor shall have been duly elected and qualified.
Section 20. Removal.
(a)
Subject to any limitations imposed by applicable law, the Board of Directors or any director
may be removed from office at any time (i) with cause by the affirmative vote of the holders of a majority of the voting power of all
then-outstanding shares of capital stock of the corporation entitled to vote generally at an election of directors, or (ii) without
cause by the affirmative vote of the holders of a majority of the voting power of all then-outstanding shares of capital stock of the
corporation, entitled to vote generally at an election of directors.
Section 21. Meetings.
(a)
Regular Meetings. Unless otherwise restricted by the Restated
Certificate of Incorporation, regular meetings of the Board of Directors may be held at any time or date and at any place within or without
the State of Delaware which has been designated by
the Board of Directors
and publicized among all directors, either orally or in writing, by telephone, including a voice-messaging system or other system designed
to record and communicate messages, facsimile, telegraph or telex, or by electronic mail or other electronic means. No further notice
shall be required for regular meetings of the Board of Directors.
(b)
Special Meetings. Unless otherwise restricted by the Restated
Certificate of Incorporation, special meetings of the Board of Directors may be held at any time and place within or without the State
of Delaware whenever called by the Chairman of the Board, the Chief Executive Officer or a majority of the directors then in office.
(c)
Meetings by Electronic Communications Equipment. Any member
of the Board of Directors, or of any committee thereof, may participate in a meeting by means of conference telephone or other communications
equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting by such means
shall constitute presence in person at such meeting.
(d)
Notice of Special Meetings. Notice of the time and place
of all special meetings of the Board of Directors shall be orally or in writing, by telephone, including a voice messaging system or other
system or technology designed to record and communicate messages, facsimile, telegraph or telex, or by electronic mail or other electronic
means, during normal business hours, at least 24 hours before the date and time of the meeting. If notice is sent by U.S. mail, it
shall be sent by first class mail, charges prepaid, at least three days before the date of the meeting. Notice of any meeting may be waived
in writing, or by electronic transmission, at any time before or after the meeting and will be waived by any director by attendance thereat,
except when the director attends the meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction
of any business because the meeting is not lawfully called or convened.
(e)
Waiver of Notice. The transaction of all business at any
meeting of the Board of Directors, or any committee thereof, however called or noticed, or wherever held, shall be as valid as though
had at a meeting duly held after regular call and notice, if a quorum be present and if, either before or after the meeting, each of the
directors not present who did not receive notice shall sign a written waiver of notice or shall waive notice by electronic transmission.
All such waivers shall be filed with the corporate records or made a part of the minutes of the meeting.
Section 22. Quorum
and Voting.
(a)
Unless the Restated Certificate of Incorporation requires a greater number and, except with respect
to questions related to indemnification arising under Section 43 for which a quorum shall be one-third of the exact number of
directors fixed from time to time, a quorum of the Board of Directors shall consist of a majority of the exact number of directors fixed
from time to time by the Board of Directors in accordance with the Restated Certificate of Incorporation; provided, however, at
any meeting whether a quorum be present or otherwise, a majority of the directors present may adjourn from time to time until the time
fixed for the next regular meeting of the Board of Directors, without notice other than by announcement at the meeting.
(b)
At each meeting of the Board of Directors at which a quorum is present, all questions and business
shall be determined by the affirmative vote of a majority of the directors present, unless a different vote be required by law, the Restated
Certificate of Incorporation or these Amended and Restated Bylaws.
Section 23. Action
Without Meeting. Unless otherwise restricted by the Restated Certificate of Incorporation or these Amended and Restated Bylaws, any
action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting,
if all members of the Board of Directors or committee, as the case may be, consent thereto in writing or by electronic transmission, and
such writing or writings or transmission or transmissions are filed with the minutes of proceedings of the Board of Directors or committee.
Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained
in electronic form.
Section 24. Fees
and Compensation. Directors shall be entitled to such compensation for their services as may be approved by the Board of Directors,
including, if so approved, by resolution of the Board of Directors, a fixed sum and expenses of attendance, if any, for attendance at
each regular or special meeting of the Board of Directors and at any meeting of a committee of the Board of Directors. Nothing herein
contained shall be construed to preclude any director from serving the corporation in any other capacity as an officer, agent, employee,
or otherwise and receiving compensation therefor.
Section 25. Committees.
(a)
Executive Committee. The Board of Directors may appoint
an Executive Committee to consist of one or more members of the Board of Directors. The Executive Committee, to the extent permitted by
law and provided in the resolution of the Board of Directors shall have and may exercise all the powers and authority of the Board of
Directors in the management of the business and affairs of the corporation, and may authorize the seal of the corporation to be affixed
to all papers which may require it; but no such committee shall have the power or authority in reference to (i) approving or adopting,
or recommending to the stockholders, any action or matter expressly required by the DGCL to be submitted to stockholders for approval,
or (ii) adopting, amending or repealing any bylaw of the corporation.
(b)
Other Committees. The Board of Directors may, from time
to time, appoint such other committees as may be permitted by law. Such other committees appointed by the Board of Directors shall consist
of one or more members of the Board of Directors and shall have such powers and perform such duties as may be prescribed by the resolution
or resolutions creating such committees, but in no event shall any such committee have the powers denied to the Executive Committee in
these Amended and Restated Bylaws.
(c)
Term. The Board of Directors, subject to any requirements
of any outstanding series of Preferred Stock and the provisions of subsections (a) or (b) of this Section 25, may at any time
increase or decrease the number of members of a committee or terminate the existence of a committee. The membership of a committee member
shall terminate on the date of his death or voluntary resignation from the committee or from the Board of Directors. The Board of Directors
may at any time for any reason remove any individual
committee member
and the Board of Directors may fill any committee vacancy created by death, resignation, removal or increase in the number of members
of the committee. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any
absent or disqualified member at any meeting of the committee, and, in addition, in the absence or disqualification of any member of a
committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not he or they constitute
a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified
member.
(d)
Meetings. Unless the Board of Directors shall otherwise
provide, regular meetings of the Executive Committee or any other committee appointed pursuant to this Section 25 shall be held at
such times and places as are determined by the Board of Directors, or by any such committee, and when notice thereof has been given to
each member of such committee, no further notice of such regular meetings need be given thereafter. Special meetings of any such committee
may be held at any place which has been determined from time to time by such committee, and may be called by any director who is a member
of such committee, upon notice to the members of such committee of the time and place of such special meeting given in the manner provided
for the giving of notice to members of the Board of Directors of the time and place of special meetings of the Board of Directors. Notice
of any special meeting of any committee may be waived in writing at any time before or after the meeting and will be waived by any director
by attendance thereat, except when the director attends such special meeting for the express purpose of objecting, at the beginning of
the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Unless otherwise provided by the
Board of Directors in the resolutions authorizing the creation of the committee, a majority of the authorized number of members of any
such committee shall constitute a quorum for the transaction of business, and the act of a majority of those present at any meeting at
which a quorum is present shall be the act of such committee.
Section 26. Organization.
At every meeting of the directors, the Chairman of the Board of Directors, or, if a Chairman has not been appointed or is absent,
the Chief Executive Officer (if a director), or if the Chief Executive Officer is absent, the President (if a director), or, in the absence
of any such person, a chairman of the meeting chosen by a majority of the directors present, shall preside over the meeting. The Secretary,
or in his absence, any Assistant Secretary directed to do so by the Chairman, shall act as secretary of the meeting.
ARTICLE V
OFFICERS
Section 27. Officers
Designated. The officers of the corporation shall include, if and when designated by the Board of Directors, the Chairman of the Board
of Directors, the Chief Executive Officer, the President, one or more Vice Presidents, the Secretary, the Chief Financial Officer and
the Treasurer. The Board of Directors may also appoint one or more Assistant Secretaries, Assistant Treasurers and such other officers
and agents with such powers and duties as it shall deem necessary. The Board of Directors may assign such additional titles to one or
more of the officers as it shall deem appropriate. Any one person may hold any number of offices of the corporation at any one time, unless
specifically prohibited therefrom by law. The
salaries and other
compensation of the officers of the corporation shall be fixed by or in the manner designated by the Board of Directors.
Section 28. Tenure
and Duties of Officers.
(a)
General. All officers shall hold office at the pleasure
of the Board of Directors and until their successors shall have been duly elected and qualified, unless sooner removed. Any officer elected
or appointed by the Board of Directors may be removed at any time by the Board of Directors. If the office of any officer becomes vacant
for any reason, the vacancy may be filled by the Board of Directors.
(b)
Duties of Chairman of the Board of Directors. The Chairman
of the Board of Directors, when present, shall preside at all meetings of the stockholders and the Board of Directors. The Chairman of
the Board of Directors shall perform other duties commonly incident to the office and shall also perform such other duties and have such
other powers, as the Board of Directors shall designate from time to time. If there is no President or Chief Executive Officer, unless
otherwise determined by the Board of Directors, then the Chairman of the Board of Directors shall also serve as the President of the corporation
and shall have the powers and duties prescribed in paragraph (c) of this Section 28.
(c)
Duties of Chief Executive Officer. The Chief Executive Officer
shall preside at all meetings of the stockholders and at all meetings of the Board of Directors, unless the Chairman of the Board of Directors
has been appointed and is present. Unless some other officer has been elected Chief Executive Officer of the corporation, the President
shall be the chief executive officer of the corporation and shall, subject to the control of the Board of Directors, have general supervision,
direction and control of the business and officers of the corporation. To the extent that a Chief Executive Officer has been appointed,
all references in these Bylaws to the President shall be deemed references to the Chief Executive Officer. The Chief Executive Officer
shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers, as the
Board of Directors shall designate from time to time.
(d)
Duties of President. The President shall preside at all
meetings of the stockholders and at all meetings of the Board of Directors, unless the Chairman of the Board of Directors or the Chief
Executive Officer has been appointed and is present. Unless another officer has been appointed Chief Executive Officer of the corporation,
the President shall be the chief executive officer of the corporation and shall, subject to the control of the Board of Directors, have
general supervision, direction and control of the business and officers of the corporation. The President shall perform other duties commonly
incident to the office and shall also perform such other duties and have such other powers, as the Board of Directors shall designate
from time to time.
(e)
Duties of Vice Presidents. The Vice Presidents may assume
and perform the duties of the President in the absence or disability of the President or whenever the office of President is vacant. The
Vice Presidents shall perform other duties commonly incident to their office and shall also perform such other duties and have such other
powers as the Board of Directors or the Chief Executive Officer shall designate from time to time.
(f)
Duties of Secretary. The Secretary shall attend all meetings
of the stockholders and of the Board of Directors and shall record all acts and proceedings thereof in the minute book of the corporation.
The Secretary shall give notice in conformity with these Amended and Restated Bylaws of all meetings of the stockholders and of all meetings
of the Board of Directors and any committee thereof requiring notice. The Secretary shall perform all other duties provided for in these
Amended and Restated Bylaws and other duties commonly incident to the office and shall also perform such other duties and have such other
powers, as the Board of Directors shall designate from time to time. The President may direct any Assistant Secretary to assume and perform
the duties of the Secretary in the absence or disability of the Secretary, and each Assistant Secretary shall perform other duties commonly
incident to the office and shall also perform such other duties and have such other powers as the Board of Directors or the President
shall designate from time to time.
(g)
Duties of Chief Financial Officer. The Chief Financial Officer
shall keep or cause to be kept the books of account of the corporation in a thorough and proper manner and shall render statements of
the financial affairs of the corporation in such form and as often as required by the Board of Directors or the President. The Chief Financial
Officer, subject to the order of the Board of Directors, shall have the custody of all funds and securities of the corporation. The Chief
Financial Officer shall perform other duties commonly incident to the office and shall also perform such other duties and have such other
powers as the Board of Directors or the President shall designate from time to time. The President may direct the Treasurer or any Assistant
Treasurer, or the Controller or any Assistant Controller to assume and perform the duties of the Chief Financial Officer in the absence
or disability of the Chief Financial Officer, and each Treasurer and Assistant Treasurer and each Controller and Assistant Controller
shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers as the
Board of Directors or the President shall designate from time to time.
Section 29. Delegation
of Authority. The Board of Directors may from time to time delegate the powers or duties of any officer to any other officer or agent,
notwithstanding any provision hereof.
Section 30. Resignations.
Any officer may resign at any time by giving notice in writing or by electronic transmission to the Board of Directors or to the President
or to the Secretary. Any such resignation shall be effective when received by the person or persons to whom such notice is given, unless
a later time is specified therein, in which event the resignation shall become effective at such later time. Unless otherwise specified
in such notice, the acceptance of any such resignation shall not be necessary to make it effective. Any resignation shall be without prejudice
to the rights, if any, of the corporation under any contract with the resigning officer.
Section 31. Removal.
Any officer may be removed from office at any time, either with or without cause, by the affirmative vote of a majority of the directors
in office at the time, or by the unanimous written consent of the directors in office at the time, or by any committee or by the Chief
Executive Officer or by other superior officers upon whom such power of removal may have been conferred by the Board of Directors.
ARTICLE VI
EXECUTION OF CORPORATE INSTRUMENTS AND
VOTING OF SECURITIES OWNED BY THE CORPORATION
Section 32. Execution
of Corporate Instruments. The Board of Directors may, in its discretion, determine the method and designate the signatory officer
or officers, or other person or persons, to execute on behalf of the corporation any corporate instrument or document, or to sign on behalf
of the corporation the corporate name without limitation, or to enter into contracts on behalf of the corporation, except where otherwise
provided by law or these Amended and Restated Bylaws, and such execution or signature shall be binding upon the corporation.
All checks and drafts
drawn on banks or other depositaries on funds to the credit of the corporation or in special accounts of the corporation shall be signed
by such person or persons as the Board of Directors shall authorize so to do.
Unless authorized or
ratified by the Board of Directors or within the agency power of an officer, no officer, agent or employee shall have any power or authority
to bind the corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose or for any amount.
Section 33. Voting
of Securities Owned by the Corporation. All stock and other securities of other corporations owned or held by the corporation for
itself, or for other parties in any capacity, shall be voted, and all proxies with respect thereto shall be executed, by the person authorized
so to do by resolution of the Board of Directors, or, in the absence of such authorization, by the Chairman of the Board of Directors,
the Chief Executive Officer, the President, or any Vice President.
ARTICLE VII
SHARES OF STOCK
Section 34. Form
and Execution of Certificates. The shares of the corporation shall be represented by certificates, or shall be uncertificated. Certificates
for the shares of stock of the corporation, if any, shall be in such form as is consistent with the Restated Certificate of Incorporation
and applicable law. Every holder of stock represented by certificate in the corporation shall be entitled to have a certificate signed
by or in the name of the corporation by the Chairman of the Board of Directors, the Chief Executive Officer, the President or any Vice
President and by the Chief Financial Officer, Treasurer or Assistant Treasurer or the Secretary or Assistant Secretary, certifying the
number of shares owned by him in the corporation. Any or all of the signatures on the certificate may be facsimiles. In case any officer,
transfer agent, or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such
officer, transfer agent, or registrar before such certificate is issued, it may be issued with the same effect as if he were such officer,
transfer agent, or registrar at the date of issue. Each certificate, if any, shall state upon the face or back thereof, in full or in
summary, all of the powers, designations, preferences, and rights, and the limitations or restrictions of the shares authorized to be
issued or shall, except as otherwise required by law, set forth on the face or back a statement that the corporation will furnish without
charge to each stockholder who so
requests the powers,
designations, preferences and relative, participating, optional, or other special rights of each class of stock or series thereof and
the qualifications, limitations or restrictions of such preferences and/or rights. Within a reasonable time after the issuance or transfer
of uncertificated stock, the corporation shall send to the registered owner thereof a written notice containing the information required
to be set forth or stated on certificates pursuant to this section or otherwise required by law or with respect to this section a statement
that the corporation will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative
participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions
of such preferences and/or rights.
Section 35. Lost
Certificates. A new certificate or certificates shall be issued in place of any certificate or certificates theretofore issued by
the corporation alleged to have been lost, stolen, or destroyed, upon the making of an affidavit of that fact by the person claiming the
certificate of stock to be lost, stolen, or destroyed. The corporation may require, as a condition precedent to the issuance of a new
certificate or certificates, the owner of such lost, stolen, or destroyed certificate or certificates, or the owner’s legal representative,
to agree to indemnify the corporation in such manner as it shall require or to give the corporation a surety bond in such form and amount
as it may direct as indemnity against any claim that may be made against the corporation with respect to the certificate alleged to have
been lost, stolen, or destroyed.
Section 36. Transfers.
(a)
Transfers of record of shares of stock of the corporation shall be made only upon its books by
the holders thereof, in person or by attorney duly authorized, and, in the case of stock represented by certificate, upon the surrender
of a properly endorsed certificate or certificates for a like number of shares.
(b)
The corporation shall have power to enter into and perform any agreement with any number of stockholders
of any one or more classes of stock of the corporation to restrict the transfer of shares of stock of the corporation of any one or more
classes owned by such stockholders in any manner not prohibited by the DGCL.
Section 37. Fixing
Record Dates.
(a)
In order that the corporation may determine the stockholders entitled to notice of or to vote
at any meeting of stockholders or any adjournment thereof, the Board of Directors may fix, in advance, a record date, which record date
shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date
shall, subject to applicable law, not be more than 60 nor less than 10 days before the date of such meeting. If no record date is
fixed by the Board of Directors, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders
shall be at the close of business on the day next preceding the day on which notice is given, or if notice is waived, at the close of
business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice
of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of
Directors may fix a new record date for the adjourned meeting.
(b)
In order that the corporation may determine the stockholders entitled to receive payment of
any dividend or other distribution or allotment of any rights or the stockholders entitled to exercise any rights in respect of any change,
conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix, in advance, a record date,
which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall
be not more than 60 days prior to such action. If no record date is fixed, the record date for determining stockholders for any such
purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto.
Section 38. Registered
Stockholders. The corporation shall be entitled to recognize the exclusive right of a person registered on its books as the owner
of shares to receive dividends, and to vote as such owner, and shall not be bound to recognize any equitable or other claim to or interest
in such share or shares on the part of any other person whether or not it shall have express or other notice thereof, except as otherwise
provided by the laws of Delaware.
ARTICLE VIII
OTHER SECURITIES OF THE CORPORATION
Section 39. Execution
of Other Securities. All bonds, debentures and other corporate securities of the corporation, other than stock certificates (covered
in Section 34), may be signed by the Chairman of the Board of Directors, the Chief Executive Officer, the President or any Vice President,
or such other person as may be authorized by the Board of Directors, and the corporate seal impressed thereon or a facsimile of such seal
imprinted thereon and attested by the signature of the Secretary or an Assistant Secretary, or the Chief Financial Officer or Treasurer
or an Assistant Treasurer; provided, however, that where any such bond, debenture or other corporate security shall be authenticated
by the manual signature, or where permissible facsimile signature, of a trustee under an indenture pursuant to which such bond, debenture
or other corporate security shall be issued, the signatures of the persons signing and attesting the corporate seal on such bond, debenture
or other corporate security may be the imprinted facsimile of the signatures of such persons. Interest coupons appertaining to any such
bond, debenture or other corporate security, authenticated by a trustee as aforesaid, shall be signed by the Treasurer or an Assistant
Treasurer of the corporation or such other person as may be authorized by the Board of Directors, or bear imprinted thereon the facsimile
signature of such person. In case any officer who shall have signed or attested any bond, debenture or other corporate security, or whose
facsimile signature shall appear thereon or on any such interest coupon, shall have ceased to be such officer before the bond, debenture
or other corporate security so signed or attested shall have been delivered, such bond, debenture or other corporate security nevertheless
may be adopted by the corporation and issued and delivered as though the person who signed the same or whose facsimile signature shall
have been used thereon had not ceased to be such officer of the corporation.
ARTICLE IX
DIVIDENDS
Section 40. Declaration
of Dividends. Dividends upon the capital stock of the corporation, subject to the provisions of the Restated Certificate of Incorporation
and applicable
law, if any, may
be declared by the Board of Directors pursuant to law at any regular or special meeting. Dividends may be paid in cash, in property, or
in shares of the capital stock, subject to the provisions of the Restated Certificate of Incorporation and applicable law.
Section 41. Dividend
Reserve. Before payment of any dividend, there may be set aside out of any funds of the corporation available for dividends such sum
or sums as the Board of Directors from time to time, in their absolute discretion, think proper as a reserve or reserves to meet contingencies,
or for equalizing dividends, or for repairing or maintaining any property of the corporation, or for such other purpose as the Board of
Directors shall think conducive to the interests of the corporation, and the Board of Directors may modify or abolish any such reserve
in the manner in which it was created.
ARTICLE X
FISCAL YEAR
Section 42. Fiscal
Year. The fiscal year of the corporation shall be fixed by resolution of the Board of Directors.
ARTICLE XI
INDEMNIFICATION
Section 43. Indemnification
of Directors, Officers, Employees and Other Agents.
(a)
Directors and Officers. The corporation shall indemnify
its directors and officers to the fullest extent not prohibited by the DGCL or any other applicable law; provided, however, that
the corporation may modify the extent of such indemnification by individual contracts with its directors and officers; and, provided,
further, that the corporation shall not be required to indemnify any director or officer in connection with any proceeding (or part
thereof) initiated by such person, unless (i) such indemnification is expressly required to be made by law, (ii) the proceeding
was authorized by the Board of Directors of the corporation, (iii) such indemnification is provided by the corporation, in its sole
discretion, pursuant to the powers vested in the corporation under the DGCL or any other applicable law or (iv) such indemnification
is required to be made under subsection (d).
(b)
Employees and Other Agents. The corporation shall have power
to indemnify its employees and other agents as set forth in the DGCL or any other applicable law. The Board of Directors shall have the
power to delegate the determination of whether indemnification shall be given to any such employee or other persons as the Board of Directors
shall determine.
(c)
Expenses. The corporation shall advance to any person who
was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil,
criminal, administrative or investigative, by reason of the fact that he is or was a director or officer of the corporation, or is or
was serving at the request of the corporation as a director or officer of another corporation, partnership, joint venture, trust or other
enterprise, prior to the final disposition of the proceeding, promptly following request therefor, all expenses incurred by any director
or officer in connection with such proceeding provided, however, that if the DGCL requires, an advancement of expenses incurred by a
director or officer
in his or her capacity as a director or officer (and not in any other capacity in which service was or is rendered by such indemnitee,
including, without limitation, service to an employee benefit plan) shall be made only upon delivery to the corporation of an undertaking
(hereinafter an “undertaking”), by or on behalf of such indemnitee, to repay all amounts so advanced if it shall ultimately
be determined by final judicial decision from which there is no further right to appeal (hereinafter a “final adjudication”)
that such indemnitee is not entitled to be indemnified for such expenses under this Section or otherwise.
Notwithstanding
the foregoing, unless otherwise determined pursuant to paragraph (e) of this Section, no advance shall be made by the corporation
to an officer of the corporation (except by reason of the fact that such officer is or was a director of the corporation, in which event
this paragraph shall not apply) in any action, suit or proceeding, whether civil, criminal, administrative or investigative, if a determination
is reasonably and promptly made (i) by the Board of Directors by a majority vote of directors who were not parties to the proceeding,
even if not a quorum, or (ii) by a committee of such directors designated by a majority vote of such directors, even though less
than a quorum, or (iii) if there are no such directors, or such directors so direct, by independent legal counsel in a written opinion,
that the facts known to the decision-making party at the time such determination is made demonstrate clearly and convincingly that such
person acted in bad faith or in a manner that such person did not believe to be in or not opposed to the best interests of the corporation.
(d)
Enforcement. Without the necessity of entering into an express
contract, all rights to indemnification and advances to directors and officers under this Section shall be deemed to be contractual rights
and be effective to the same extent and as if provided for in a contract between the corporation and the director or officer. Any right
to indemnification or advances granted by this Section to a director or officer shall be enforceable by or on behalf of the person holding
such right in any court of competent jurisdiction if (i) the claim for indemnification or advances is denied, in whole or in part,
or (ii) no disposition of such claim is made within 90 days of request therefor. The claimant in such enforcement action, if
successful in whole or in part, shall be entitled to be paid also the expense of prosecuting the claim. In connection with any claim for
indemnification, the corporation shall be entitled to raise as a defense to any such action that the claimant has not met the standards
of conduct that make it permissible under the DGCL or any other applicable law for the corporation to indemnify the claimant for the amount
claimed. In connection with any claim by an officer of the corporation (except in any action, suit or proceeding, whether civil, criminal,
administrative or investigative, by reason of the fact that such officer is or was a director of the corporation) for advances, the corporation
shall be entitled to raise a defense as to any such action clear and convincing evidence that such person acted in bad faith or in a manner
that such person did not believe to be in or not opposed to the best interests of the corporation, or with respect to any criminal action
or proceeding that such person acted without reasonable cause to believe that his conduct was lawful. Neither the failure of the corporation
(including its Board of Directors, independent legal counsel or its stockholders) to have made a determination prior to the commencement
of such action that indemnification of the claimant is proper in the circumstances because the officer or director has met the applicable
standard of conduct set forth in the DGCL or any other applicable law, nor an actual determination by the corporation (including its Board
of Directors, independent legal counsel or its stockholders) that the claimant has not met such applicable standard of conduct, shall
be a defense to the action or create a presumption that claimant has not
met the applicable
standard of conduct. In any suit brought by a director or officer to enforce a right to indemnification or to an advancement of expenses
hereunder, the burden of proving that the director or officer is not entitled to be indemnified, or to such advancement of expenses, under
this Section or otherwise shall be on the corporation.
(e)
Non-Exclusivity of Rights. The rights conferred on any person
by this Bylaw shall not be exclusive of any other right which such person may have or hereafter acquire under any applicable statute,
provision of the Restated Certificate of Incorporation, Amended and Restated Bylaws, agreement, vote of stockholders or disinterested
directors or otherwise, both as to action in such person’s official capacity and as to action in another capacity while holding
office. The corporation is specifically authorized to enter into individual contracts with any or all of its directors, officers, employees
or agents respecting indemnification and advances, to the fullest extent not prohibited by the DGCL, or by any other applicable law.
(f)
Survival of Rights. The rights conferred on any person by
this Bylaw shall continue as to a person who has ceased to be a director or officer and shall inure to the benefit of the heirs, executors
and administrators of such a person.
(g)
Insurance. To the fullest extent permitted by the DGCL or
any other applicable law, the corporation, upon approval by the Board of Directors, may purchase insurance on behalf of any person required
or permitted to be indemnified pursuant to this Section.
(h)
Amendments. Any repeal or modification of this Section shall
only be prospective and shall not affect the rights under this Bylaw in effect at the time of the alleged occurrence of any action or
omission to act that is the cause of any proceeding against any agent of the corporation.
(i)
Saving Clause. If this Bylaw or any portion hereof shall
be invalidated on any ground by any court of competent jurisdiction, then the corporation shall nevertheless indemnify each director and
officer to the full extent not prohibited by any applicable portion of this Section that shall not have been invalidated, or by any other
applicable law. If this Section shall be invalid due to the application of the indemnification provisions of another jurisdiction, then
the corporation shall indemnify each director and officer to the full extent under any other applicable law.
(j)
Certain Definitions. For the purposes of this Bylaw, the
following definitions shall apply:
(1)
The term “proceeding” shall be broadly construed and shall include, without limitation,
the investigation, preparation, prosecution, defense, settlement, arbitration and appeal of, and the giving of testimony in, any threatened,
pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative.
(2)
The term “expenses” shall be broadly construed and shall include, without limitation,
court costs, attorneys’ fees, witness fees, fines, amounts paid in settlement or judgment and any other costs and expenses of any
nature or kind incurred in connection with any proceeding.
(3)
The term the “corporation” shall include, in addition to the resulting corporation,
any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate
existence had continued, would have had power and authority to indemnify its directors, officers, and employees or agents, so that any
person who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such
constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise,
shall stand in the same position under the provisions of this Section 43 with respect to the resulting or surviving corporation as
he would have with respect to such constituent corporation if its separate existence had continued.
(4)
References to a “director,” “officer,” “employee,” or “agent”
of the corporation shall include, without limitation, situations where such person is serving at the request of the corporation as, respectively,
a director, officer, employee, trustee or agent of another corporation, partnership, joint venture, trust or other enterprise.
(5)
References to “other enterprises” shall include employee benefit plans; references
to “fines” shall include any excise taxes assessed on a person with respect to an employee benefit plan; and references to
“serving at the request of the corporation” shall include any service as a director, officer, employee or agent of the corporation
which imposes duties on, or involves services by, such director, officer, employee, or agent with respect to an employee benefit plan,
its participants, or beneficiaries; and a person who acted in good faith and in a manner such person reasonably believed to be in the
interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner “not opposed
to the best interests of the corporation” as referred to in this Section.
ARTICLE XII
NOTICES
Section 44. Notices.
(a)
Notice to Stockholders. Written notice to stockholders of
stockholder meetings shall be given as provided in Section 7 herein. Without limiting the manner by which notice may otherwise be
given effectively to stockholders under any agreement or contract with such stockholder and, except as otherwise required by law, written
notice to stockholders for purposes other than stockholder meetings may be sent by U.S. mail or nationally recognized overnight courier,
or by facsimile, telegraph or telex or by electronic mail or other electronic means. Without limiting the manner by which notice otherwise
may be given effectively to stockholders pursuant to the DGCL, the Restated Certificate of Incorporation or these Amended and Restated
Bylaws, any notice shall be effective if given by a form of electronic transmission in the manner provided in Section 232 of the
DGCL.
(b)
Notice to Directors. Any notice required to be given to
any director may be given by the method stated in subsection (a), as otherwise provided in these Amended and Restated Bylaws, or by overnight
delivery service, facsimile, telex or telegram, except that such notice other than one which is delivered personally shall be sent to
such address
as such director
shall have filed in writing with the Secretary, or, in the absence of such filing, to the last known post office address of such director.
(c)
Affidavit of Mailing. An affidavit of mailing, executed
by a duly authorized and competent employee of the corporation or its transfer agent appointed with respect to the class of stock affected,
or other agent, specifying the name and address or the names and addresses of the stockholder or stockholders, or director or directors,
to whom any such notice or notices was or were given, and the time and method of giving the same, shall in the absence of fraud, be prima
facie evidence of the facts therein contained.
(d)
Methods of Notice. It shall not be necessary that the same
method of giving notice be employed in respect of all recipients of notice, but one permissible method may be employed in respect of any
one or more, and any other permissible method or methods may be employed in respect of any other or others.
(e)
Notice to Person With Whom Communication is Unlawful. Whenever
notice is required to be given, under any provision of law or of the Restated Certificate of Incorporation or Restated Bylaws of the corporation,
to any person with whom communication is unlawful, the giving of such notice to such person shall not be required and there shall be no
duty to apply to any governmental authority or agency for a license or permit to give such notice to such person. Any action or meeting
which shall be taken or held without notice to any such person with whom communication is unlawful shall have the same force and effect
as if such notice had been duly given. In the event that the action taken by the corporation is such as to require the filing of a certificate
under any provision of the DGCL, the certificate shall state, if such is the fact and if notice is required, that notice was given to
all persons entitled to receive notice, except such persons with whom communication is unlawful.
(f)
Notice to Stockholders Sharing an Address. Except as otherwise
prohibited under the DGCL, any notice given under the provisions of the DGCL, the Restated Certificate of Incorporation or the Restated
Bylaws shall be effective if given by a single written notice to stockholders who share an address if consented to by the stockholders
at that address to whom such notice is given. Such consent shall have been deemed to have been given if such stockholder fails to object
in writing to the corporation within 60 days of having been given notice by the corporation of its intention to send the single notice.
Any consent shall be revocable by the stockholder by written notice to the corporation.
ARTICLE XIII
AMENDMENTS
Section 45. Bylaw
Amendments. Subject to these Bylaws or the provisions of the Restated Certificate of Incorporation, the Board of Directors is expressly
empowered to adopt, amend or repeal the Bylaws of the corporation. Any adoption, amendment or repeal of the Bylaws of the corporation
by the Board of Directors shall require the approval of a majority of the authorized number of Directors. The stockholders shall also
have power to adopt, amend or repeal the Bylaws of the corporation; provided, however, that, in addition to any vote of the holders of
any class or series of stock of the corporation required by law or by the Restated Certificate of Incorporation, the affirmative vote
of the holders of at least a majority of the voting
power of all of the
then-outstanding shares of the capital stock of the corporation entitled to vote generally in the election of directors, voting together
as a single class, shall be required to adopt, amend or repeal any provision of the Bylaws of the corporation.
ARTICLE XIV
LOANS TO OFFICERS OR EMPLOYEES
Section 46. Loans
to Officers or Employees. Except as otherwise prohibited by applicable law, the corporation may lend money to, or guarantee any obligation
of, or otherwise assist any officer or other employee of the corporation or of its subsidiaries, including any officer or employee who
is a director of the corporation or its subsidiaries, whenever, in the judgment of the Board of Directors, such loan, guarantee or assistance
may reasonably be expected to benefit the corporation. The loan, guarantee or other assistance may be with or without interest and may
be unsecured, or secured in such manner as the Board of Directors shall approve, including, without limitation, a pledge of shares of
stock of the corporation. Nothing in these Amended and Restated Bylaws shall be deemed to deny, limit or restrict the powers of guaranty
or warranty of the corporation at common law or under any statute.
ARTICLE XV
SECTION 2115
Section 47. Section
2115. At any time or times that the corporation is subject to Section 2115(b) of the CGCL, then these Amended and Restated Bylaws
shall be interpreted so as to be consistent with, and shall be deemed to include, those provisions of the CGCL that are required by applicable
law to apply to the corporation.
ARTICLE XVI
FORUM
Section
48. Forum. Unless the corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State
of Delaware shall, to the fullest extent permitted by law, be the sole and exclusive forum for (i) any derivative action or proceeding
brought on behalf of the corporation; (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer
or other employee of the corporation to the corporation or the corporation’s stockholders; (iii) any action asserting a claim
against the corporation or any director or officer or other employee of the corporation arising pursuant to any provision of the DGCL,
the certificate of incorporation or the Bylaws of the corporation, or as to which the DGCL confers jurisdiction on the Court of Chancery
of the State of Delaware; or (iv) any action asserting a claim against the corporation or any director or officer or other employee
of the corporation governed by the internal affairs doctrine, in all cases subject to the court’s having personal jurisdiction over
the indispensable parties named as defendants (including without limitation as a result of the consent of such indispensable parties to
the personal jurisdiction of such court). If any action the subject matter of which is within the scope of the preceding sentence is filed
in a court other than a court located within the State of Delaware (a “Foreign Action”) in the name of any stockholder,
such stockholder shall be deemed to have consented to (i) the personal jurisdiction of the state and federal courts located within the
State of Delaware in connection with any action brought in any such court to enforce the preceding sentence and (ii)
having service of
process made upon such stockholder in any such action by service upon such stockholder’s counsel in the Foreign Action as agent
for such stockholder. This paragraph shall not apply to suits brought to enforce a duty or liability created by the Securities Act of
1933, as amended (the “Securities Act”), the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or any other claim for which the federal courts have exclusive jurisdiction.
Unless
the corporation consents in writing to the selection of an alternative forum, the federal district courts of the United States of America
shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of
action arising under the Securities Act.
Any
person or entity purchasing or otherwise acquiring or holding any interest in shares of capital stock of the corporation shall be deemed
to have notice of and consented to the provisions of this Article XVI.
DMK Pharmaceuticals Corporation 8-K
Exhibit 99.1
Adamis Pharmaceuticals
Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus
Company to begin
trading under new ticker symbol “DMK” on September 8, 2023
SAN DIEGO, September 7, 2023
--
Adamis Pharmaceuticals Corporation
(NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the company changed
its name to DMK Pharmaceuticals Corporation in order to better reflect its new strategic focus on advancing small molecules for the treatment
of substance use disorders. In conjunction with the name change, the company’s common stock is expected to trade under the new Nasdaq
ticker symbol “DMK” on or about September 8, 2023. The CUSIP number for the common stock, 00547W307, will remain unchanged.
“The
new DMK Pharmaceuticals is committed to developing groundbreaking and innovative therapies to establish itself as a leader in the treatment
of substance abuse including opioid and alcohol use disorders,” said Eboo Versi, MD, PhD, CEO of Adamis, “Rebranding the
company signifies our new strategic vision and reinforces our commitment to a renewed corporate strategy. Along with our flagship approved
treatment for emergency treatment of opioid overdose, ZIMHI®, our lead clinical stage compound, DPI-125 will be our core focus. DPI-125
is a novel molecule for the treatment of opioid use disorder. Currently approved therapies are old and the vast majority of sufferers
are not getting this medical treatment. I believe this is because they have unfavorable drug scheduling resulting in limited access,
and in many cases, patients have to undergo opioid withdrawal symptoms prior to starting treatment. It is my belief that DPI-125, if
successfully developed, will receive a more favorable drug scheduling and be a more ‘patient friendly’ treatment. DPI-125
is also being developed for the treatment of moderate to severe pain. If clinical studies confirm what we suspect from animal studies,
this drug will not be addictive and as such could even help to reduce the incidence of opioid use disorder.”
DMK expects several potential significant
milestones for DPI-125 by the end of 2024 including: manufacture of a transdermal delivery system; results of a respiratory depression
safety study compared to fentanyl; results of a pharmacokinetic study in humans; and results of an abuse liability study compared to current
treatments for OUD and pain relief, in each case assuming the availability of adequate funding and no unexpected developments or delays.
There can be no assurances that any of these milestones will be achieved or will be achieved within the anticipated time periods.
About DMK Pharmaceuticals
DMK Pharmaceuticals is a commercial
stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance
use disorders. DMK’s commercial products approved by the FDA include ZIMHI®
(naloxone) Injection for the treatment of opioid overdose, and
SYMJEPI®
(epinephrine) Injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. The Company is focused
on developing novel therapies for opioid use disorder (OUD) and other important neuro-based conditions where patients are currently underserved.
DMK believes its technologies are at the forefront of endorphin-inspired drug design with its mono, bi- and tri-functional small molecules
that simultaneously modulate critical networks in the nervous system. DMK has a library of approximately 750 small molecule neuropeptide
analogues and a differentiated pipeline that could address unmet medical needs by taking the novel approach to integrate with the body’s
own efforts to regain balance of disrupted physiology. The Company’s lead clinical stage product candidate, DPI-125, is being studied
as a potential novel treatment for OUD. DMK also plans to develop the compound for the treatment of moderate to severe pain. The Company’s
other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s
disease. For additional information about DMK Pharmaceuticals, please visit our
website
and follow us on
Twitter
and
LinkedIn.
Forward Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by terminology
such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,”
“intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,”
“predicts,” “potential” or “continue” or the negative of these terms or other similar words. Such
forward-looking statements include those that express plans, anticipation, intent, contingencies, goals, targets or future development
and/or otherwise are not statements of historical fact. These statements relate to anticipated future events or future results of operations,
including, but not limited to, statements concerning (i) the ability of the Company to raise additional funds required to sustain the
Company’s ongoing operations and fund the anticipate development activities regarding DPI-125, (ii) whether, if successfully developed,
DPI-125 will receive a more favorable drug scheduling or be a more patient friendly treatment, and (iii) the potential benefits of DPI-125
if successfully developed. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors,
which may cause Adamis’ actual results to be materially different from the results anticipated by such forward-looking statements.
These statements also assume that the Company will have or are able to obtain sufficient funding to support the activities described in
this press release, continue the Company’s operations and satisfy the Company’s liabilities and obligations in a timely manner.
There can be no assurance that this will be the case. Also, such statements assume that there are no significant unexpected developments
or events that delay or prevent such activities from occurring. The Company will require additional funds to sustain operations, satisfy
our obligations and liabilities, and fund its ongoing operations. There are no assurances that required funding will be available at all
or will be available in sufficient amounts. Failure to timely obtain any required additional funding, or unexpected developments
or events, could delay the occurrence of such events or prevent the events described in any such statements from occurring which could
adversely affect our business, financial condition and results of operations. If we cannot continue as a viable entity, we might
be required to reduce or cease operations or seek dissolution and liquidation or bankruptcy protection, and our stockholders would likely
lose most or all of their investment in us. Accordingly, you should not rely upon forward-looking statements as predictions of future
events. Adamis cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur,
and actual results could differ materially from those projected in the forward-looking statements. You should not place undue reliance
on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and except as
may be required by applicable law, we undertake no obligation to update or release publicly the results of any revisions to these forward-looking
statements or to reflect events or circumstances arising after the date of this press release. Certain of these risks and additional risks,
uncertainties, and other factors are described in greater detail in Adamis’ filings from time to time with the SEC, including its
annual report on Form 10-K for the year ended December 31, 2022, and subsequent filings with the SEC, which Adamis strongly urges you
to read and consider, all of which are available free of charge on the SEC’s website at http://www.sec.gov.
Investor and Media Contact:
Robert Uhl
ICR Westwicke
v3.23.2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
+ References
+ Details
Name: |
dei_CurrentFiscalYearEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gMonthDayItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Adamis Pharmaceuticals (NASDAQ:ADMP)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024